Weiss Ratings Reiterates "Sell (D)" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Key Points

• Weiss Ratings has restated its "Sell (D)" rating for Jazz Pharmaceuticals (NASDAQ:JAZZ), indicating a negative outlook on the stock's performance.
• Multiple analysts have differing views on the stock, with Zacks improving its rating from "strong sell" to "hold", while Needham & Company and others have maintained or increased their buy ratings with target prices up to $185.00.
• Jazz Pharmaceuticals reported a significant earnings miss of ($8.25) per share for the latest quarter, which fell short of analyst expectations, despite revenue meeting consensus estimates.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)'s stock had its "sell (d)" rating restated by analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other equities research analysts have also recently weighed in on JAZZ. Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Needham & Company LLC reissued a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Morgan Stanley boosted their target price on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an "overweight" rating in a report on Wednesday, September 24th. Finally, The Goldman Sachs Group boosted their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a report on Friday, August 29th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $178.93.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $137.78 on Wednesday. The business's 50 day moving average is $125.01 and its 200-day moving average is $115.78. The stock has a market cap of $8.36 billion, a PE ratio of -20.47, a price-to-earnings-growth ratio of 8.43 and a beta of 0.28. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals has a twelve month low of $95.49 and a twelve month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, analysts predict that Jazz Pharmaceuticals will post 16.96 earnings per share for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director owned 429,973 shares of the company's stock, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 11,500 shares of company stock valued at $1,525,280 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of JAZZ. Hurley Capital LLC bought a new position in shares of Jazz Pharmaceuticals in the first quarter valued at $25,000. Picton Mahoney Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after buying an additional 269 shares in the last quarter. Spire Wealth Management raised its stake in Jazz Pharmaceuticals by 137.6% during the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after purchasing an additional 161 shares during the period. SVB Wealth LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $36,000. Finally, Hantz Financial Services Inc. raised its stake in Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company's stock valued at $38,000 after purchasing an additional 297 shares during the period. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.